NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

RXRX

Recursion Pharmaceuticals Inc

Apr 17 • 04:00PM ET

5.50

Dollar change +0.18
Percentage change 3.38	%

Healthcare • Biotechnology • USA • NASD

Peers: ABCL SDGR DNLI NBIX CRSP BEAM NTLA EDIT VRTX RGNX

| Held by: ARKK ARKG VTI VB XBI IWM VBK VXF IWO IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.66	Insider Own	23.91%	Shs Outstand	389.55M	Perf Week	21.95%
Market Cap	2.21B	Forward P/E	-	EPS next Y	-1.37	Insider Trans	-0.41%	Shs Float	305.89M	Perf Month	-16.41%
Income	-463.66M	PEG	-	EPS next Q	-0.52	Inst Own	60.30%	Short Float	28.93%	Perf Quarter	-14.06%
Sales	58.84M	P/S	37.58	EPS this Y	5.03%	Inst Trans	11.64%	Short Ratio	3.45	Perf Half Y	-17.54%
Book/sh	2.61	P/B	2.11	EPS next Y	14.64%	ROA	-44.11%	Short Interest	88.50M	Perf Year	-27.34%
Cash/sh	1.49	P/C	3.70	EPS next 5Y	20.68%	ROE	-61.89%	52W Range	3.79 - 12.36	Perf YTD	-18.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-35.28%	ROI	-41.36%	52W High	-55.50%	Beta	0.95
Dividend TTM	-	Quick Ratio	3.81	Sales past 5Y	112.62%	Gross Margin	-7.98%	52W Low	45.12%	ATR (14)	0.63
Dividend Ex-Date	-	Current Ratio	3.81	EPS Y/Y TTM	-6.86%	Oper. Margin	-814.09%	RSI (14)	48.15	Volatility	11.75% 10.65%
Employees	-	Debt/Eq	0.10	Sales Y/Y TTM	32.00%	Profit Margin	-788.02%	Recom	2.43	Target Price	8.50
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-33.50%	Payout	-	Rel Volume	0.49	Prev Close	5.32
Sales Surprise	-70.54%	EPS Surprise	-28.83%	Sales Q/Q	-58.26%	Earnings	Feb 28 BMO	Avg Volume	25.67M	Price	5.50
SMA20	2.10%	SMA50	-18.24%	SMA200	-20.49%	Trades		Volume	12,688,399	Change	3.38%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Today 09:00AM	This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? (Motley Fool)
Apr-16-25 08:30AM	HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data (PR Newswire) -5.67%
Apr-15-25 01:07AM	Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? (Insider Monkey)
Apr-14-25 03:35PM	Jim Cramer on Recursion (RXRX): "The AI Company That Has It - Backed by Jensen Huang and NVIDIA" (Insider Monkey)
09:09AM	Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? (Zacks)
06:44PM	Loading…
Apr-12-25 06:44PM	Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week? (Insider Monkey)
02:10AM	Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday? (Insider Monkey)
Apr-11-25 03:47PM	Recursion Pharma rises, Intel & Five Below fall: Trending Tickers (Yahoo Finance Video) +27.72%
02:26PM	Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win (Seeking Alpha)
11:11AM	Why Recursion Pharmaceuticals Stock Is Skyrocketing Today (Motley Fool)
Apr-09-25 10:01AM	RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study (Zacks) +17.13%
08:00AM	Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries (GlobeNewswire)
Apr-08-25 08:00AM	Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas (GlobeNewswire) -5.48%
Apr-03-25 09:30AM	Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March (Motley Fool) -9.07%
06:00AM	Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market (Fortune)
08:00AM	Loading…
Apr-01-25 08:00AM	Recursion to Participate in Upcoming Investor Conference (GlobeNewswire)
Mar-31-25 03:25PM	Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today (Motley Fool) -8.95%
Mar-30-25 09:30AM	Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? (Motley Fool)
04:30AM	Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks (Motley Fool)
Mar-29-25 11:00AM	Investors Look To Jobs Report For March As Conagra Brands, RH To Report Earnings (Seeking Alpha)
Mar-27-25 11:21AM	Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts (SeekingAlpha)
Mar-26-25 10:58AM	Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit? (InsiderMonkey) -5.51%
05:20AM	Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday? (InsiderMonkey)
Mar-20-25 05:50PM	Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today (Zacks)
Mar-18-25 10:35AM	Why Recursion Pharmaceuticals (RXRX) Went Up on Monday? (Insider Monkey) -6.58%
08:00AM	Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandj Bumpus and Mammoth Biosciences COO and CFO Elaine Sun (GlobeNewswire)
06:49AM	Big tech meets biotech: Recursion and the AI gold rush in pharma (Pharmaceutical Technology)
Mar-12-25 12:31PM	Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): Were Going To Have To Hold Off (Insider Monkey)
Mar-10-25 11:47AM	Why Recursion Pharmaceuticals Stock Is Sinking Today (Motley Fool) -6.98%
Mar-08-25 10:02AM	Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? (Motley Fool)
08:30AM	Loading…
Mar-07-25 08:30AM	4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today (Motley Fool) +5.61%
04:55AM	This Biotech Stock Could Be the Best Investment of the Decade (Motley Fool)
Mar-06-25 05:03AM	Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? (Motley Fool) -5.17%
Mar-04-25 12:58PM	Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday (Insider Monkey)
12:00AM	Recursion Pharmaceuticals Inc (RXRX) Q4 2024 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
Feb-28-25 07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:47AM	Recursion Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results (GlobeNewswire)
Feb-27-25 02:34AM	AI deals are surging, and Recursions ongoing Exscientia merger points to a new world of integration (Pharma Voice) -8.03%
Feb-24-25 08:00AM	Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th (GlobeNewswire)
Feb-23-25 03:13PM	Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025? (Insider Monkey)
Feb-21-25 12:13AM	Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX) (Insider Monkey) -10.34%
Feb-19-25 02:44PM	Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
09:00AM	Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City (GlobeNewswire)
06:00AM	Recursion CEO launches pre-seed fund in response to NIH cuts (BioPharma Dive)
Feb-18-25 04:25PM	Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 (Investor's Business Daily)
03:59PM	Why Jensen Huangs Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX) (Insider Monkey)
11:00AM	Altitude Lab Startups Raise $154M in Capital (GlobeNewswire)
Feb-17-25 07:59AM	Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week (Insider Monkey)
Feb-15-25 01:47AM	Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday? (Insider Monkey)
Feb-14-25 12:07PM	Why Recursion Pharmaceuticals Stock Is Soaring Today (Motley Fool) +23.88%
Feb-13-25 05:45PM	Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why (Zacks)
08:17AM	Why Recursion Pharmaceuticals Inc. (RXRX) Surged On Wednesday (Insider Monkey)
05:19AM	Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar? (Zacks)
Feb-11-25 05:50PM	Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider (Zacks) +8.88%
Feb-07-25 07:17AM	Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday? (Insider Monkey)
Feb-05-25 05:24PM	Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference (GlobeNewswire) -8.59%
Feb-03-25 05:50PM	Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note (Zacks)
Jan-29-25 06:45AM	Is Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025? (Insider Monkey)
Jan-24-25 12:12PM	Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgans Neutral Outlook (Insider Monkey)
Jan-23-25 09:45AM	Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last? (Zacks)
Jan-22-25 11:01PM	Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday (Insider Monkey) +8.87%
Jan-21-25 04:29AM	2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 (Motley Fool) +5.36%
Jan-18-25 03:43PM	Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth (Insider Monkey)
Jan-17-25 05:58PM	Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 (PR Newswire) +5.36%
05:47AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Jan-15-25 05:50PM	Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
Jan-10-25 09:55AM	Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect? (Zacks) -5.23%
Jan-08-25 07:26AM	Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA (TipRanks)
06:32AM	AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips (The Wall Street Journal)
Jan-07-25 09:15AM	Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More (GlobeNewswire) -5.79%
Jan-06-25 08:30AM	Recursion to Present at 43rd Annual JP Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire) +5.80%
Dec-21-24 09:00AM	Is Recursion Pharmaceuticals Stock a Millionaire Maker? (Motley Fool)
08:25AM	1 Artificial Intelligence (AI) Stock That Could Soar in 2025 (Motley Fool)
Dec-20-24 04:05PM	Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire) +15.92%
Dec-15-24 08:04AM	Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX) (Insider Monkey)
Dec-12-24 08:55AM	Recursion Pharmaceuticals (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials (Insider Monkey) -7.79%
Dec-11-24 11:48AM	Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Dec-09-24 06:00PM	Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability (GlobeNewswire) -9.79%
Dec-04-24 02:01PM	Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): It Is Worthwhile Speculation (Insider Monkey)
08:45AM	Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That's Expected to be a $7.2 Billion Market by 2029 (GlobeNewswire)
Dec-03-24 08:30AM	Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma (GlobeNewswire) -6.46%
Nov-27-24 01:20PM	Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One (Benzinga) +8.32%
Nov-22-24 10:00AM	2 Innovative Stocks That Could Deliver Outsize Returns (Motley Fool)
Nov-20-24 07:00AM	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery (GlobeNewswire)
Nov-15-24 04:11PM	Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes (Investor's Business Daily) -10.64%
Nov-13-24 09:08AM	Recursion and Exscientia Shareholders Approve the Proposed Combination (GlobeNewswire)
Nov-12-24 04:54PM	Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden (GlobeNewswire)
Nov-06-24 06:55PM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
05:57PM	Recursion Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 07:45AM	Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-02-24 09:45AM	Is Recursion Pharmaceuticals a Millionaire-Maker Stock? (Motley Fool)
Nov-01-24 05:45PM	Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-30-24 05:50PM	Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks) -5.39%
08:22AM	Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th (GlobeNewswire)
Oct-26-24 09:00AM	3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock (Motley Fool)
Oct-24-24 05:50PM	Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Oct-23-24 09:00AM	Recursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech Innovation (Insider Monkey)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibson Christopher	Chief Executive Officer	Mar 27 '25	Sale	6.04	138,574	836,987	1,117,450	Mar 28 04:52 PM
Gibson Christopher	Officer	Mar 27 '25	Proposed Sale	6.04	138,574	836,987		Mar 27 12:02 PM
Gibson Christopher	Chief Executive Officer	Mar 05 '25	Sale	6.58	20,000	131,600	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '25	Sale	6.37	20,000	127,400	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Officer	Mar 06 '25	Proposed Sale	6.37	20,000	127,400		Mar 06 11:55 AM
Gibson Christopher	Officer	Mar 05 '25	Proposed Sale	6.58	20,000	131,600		Mar 05 10:13 AM
Gibson Christopher	Chief Executive Officer	Feb 06 '25	Sale	8.12	20,000	162,400	1,273,156	Feb 07 04:14 PM
Gibson Christopher	Chief Executive Officer	Feb 05 '25	Sale	7.68	20,000	153,600	1,273,156	Feb 07 04:14 PM
Gibson Christopher	Officer	Feb 06 '25	Proposed Sale	8.12	20,000	162,400		Feb 06 10:40 AM
Gibson Christopher	Officer	Feb 05 '25	Proposed Sale	7.68	20,000	153,600		Feb 05 09:44 AM
Marriott Tina	Officer	Jan 30 '25	Proposed Sale	7.49	6,000	44,947		Jan 30 04:13 PM
Secora Michael	Former Officer	Jan 17 '25	Proposed Sale	6.51	5,000	32,573		Jan 17 05:09 PM
Secora Michael	Former Officer	Jan 15 '25	Proposed Sale	6.57	15,000	98,519		Jan 15 04:12 PM
Secora Michael	Former Officer	Jan 14 '25	Proposed Sale	6.48	15,000	97,246		Jan 14 04:21 PM
Gibson Christopher	Chief Executive Officer	Jan 08 '25	Sale	7.31	20,000	146,200	736,633	Jan 13 05:26 PM
Gibson Christopher	Chief Executive Officer	Jan 10 '25	Sale	7.05	20,000	141,000	736,633	Jan 13 05:26 PM
Gibson Christopher	Officer	Jan 10 '25	Proposed Sale	7.05	20,000	141,000		Jan 10 10:58 AM
Gibson Christopher	Officer	Jan 08 '25	Proposed Sale	7.31	20,000	146,200		Jan 08 10:30 AM
Marriott Tina	Officer	Dec 26 '24	Proposed Sale	7.46	6,000	44,761		Dec 26 04:24 PM
Secora Michael	Officer	Dec 11 '24	Proposed Sale	7.48	15,000	112,182		Dec 11 04:48 PM
Secora Michael	Officer	Dec 10 '24	Proposed Sale	7.75	15,000	116,324		Dec 10 04:56 PM
Gibson Christopher	Chief Executive Officer	Dec 04 '24	Sale	7.16	20,000	143,200	736,633	Dec 06 05:46 PM
Gibson Christopher	Chief Executive Officer	Dec 05 '24	Sale	7.12	20,000	142,400	736,633	Dec 06 05:46 PM
Gibson Christopher	Officer	Dec 05 '24	Proposed Sale	7.12	20,000	142,400		Dec 05 10:29 AM
Gibson Christopher	Officer	Dec 04 '24	Proposed Sale	7.16	20,000	143,200		Dec 04 10:32 AM
Marriott Tina	Officer	Nov 21 '24	Proposed Sale	5.78	6,000	34,702		Nov 21 04:24 PM
Gibson Christopher	Chief Executive Officer	Nov 13 '24	Sale	7.74	20,000	154,800	762,656	Nov 15 06:52 PM
Gibson Christopher	Chief Executive Officer	Nov 14 '24	Sale	7.35	20,000	147,000	762,656	Nov 15 06:52 PM
Borgeson Blake	Director	Nov 12 '24	Sale	7.64	11,447	87,457	7,066,113	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 12 '24	Option Exercise	2.22	39,375	87,413	1,490,256	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 13 '24	Option Exercise	2.22	39,375	87,413	1,514,631	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 13 '24	Sale	7.66	15,000	114,876	1,499,631	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 12 '24	Sale	7.64	15,000	114,628	1,475,256	Nov 14 07:19 PM
Gibson Christopher	Officer	Nov 14 '24	Proposed Sale	7.35	20,000	147,000		Nov 14 01:06 PM
Secora Michael	Officer	Nov 13 '24	Proposed Sale	7.66	15,000	114,876		Nov 13 04:34 PM
Gibson Christopher	Officer	Nov 13 '24	Proposed Sale	7.74	20,000	154,800		Nov 13 10:11 AM
Borgeson Blake	Director	Nov 12 '24	Proposed Sale	7.64	11,447	87,458		Nov 12 04:40 PM
Secora Michael	Officer	Nov 12 '24	Proposed Sale	7.52	15,000	112,800		Nov 12 02:48 PM
Borgeson Blake	Director	Oct 29 '24	Sale	6.72	11,447	76,926	7,077,560	Oct 31 06:01 PM
Borgeson Blake	Director	Oct 29 '24	Proposed Sale	6.72	11,447	76,926		Oct 29 04:35 PM
Marriott Tina	President and COO	Oct 24 '24	Option Exercise	1.06	6,000	6,360	527,138	Oct 28 05:25 PM
Marriott Tina	President and COO	Oct 24 '24	Sale	6.31	6,000	37,855	521,138	Oct 28 05:25 PM
Marriott Tina	Officer	Oct 24 '24	Proposed Sale	6.31	6,000	37,855		Oct 24 04:22 PM
Borgeson Blake	Director	Oct 15 '24	Sale	6.67	11,447	76,326	7,089,007	Oct 17 05:27 PM
Burrell Terry-Ann	Former BOD	Oct 17 '24	Proposed Sale	6.66	404,688	2,693,813		Oct 17 05:15 PM
Borgeson Blake	Director	Oct 15 '24	Proposed Sale	6.67	11,447	76,326		Oct 15 04:42 PM
Secora Michael	Chief Financial Officer	Oct 08 '24	Option Exercise	2.22	39,375	87,413	1,441,506	Oct 10 06:40 PM
Secora Michael	Chief Financial Officer	Oct 09 '24	Option Exercise	2.22	39,375	87,413	1,465,881	Oct 10 06:40 PM
Secora Michael	Chief Financial Officer	Oct 09 '24	Sale	6.36	15,000	95,374	1,450,881	Oct 10 06:40 PM
Secora Michael	Chief Financial Officer	Oct 08 '24	Sale	6.32	15,000	94,756	1,426,506	Oct 10 06:40 PM
Secora Michael	Officer	Oct 09 '24	Proposed Sale	6.36	15,000	95,375		Oct 09 04:23 PM
Secora Michael	Officer	Oct 08 '24	Proposed Sale	6.32	15,000	94,756		Oct 08 04:19 PM
Gibson Christopher	Chief Executive Officer	Oct 02 '24	Sale	6.16	20,000	123,200	762,656	Oct 04 06:30 PM
Gibson Christopher	Chief Executive Officer	Oct 03 '24	Sale	6.08	20,000	121,600	762,656	Oct 04 06:30 PM
Borgeson Blake	Director	Oct 01 '24	Sale	6.22	11,447	71,150	7,098,428	Oct 03 04:58 PM
Gibson Christopher	Officer	Oct 03 '24	Proposed Sale	6.08	20,000	121,600		Oct 03 10:27 AM
Gibson Christopher	Officer	Oct 02 '24	Proposed Sale	6.16	20,000	123,200		Oct 02 01:31 PM
Borgeson Blake	Director	Oct 01 '24	Proposed Sale	6.51	11,447	74,520		Oct 01 02:20 PM
Marriott Tina	President and COO	Sep 26 '24	Option Exercise	1.06	6,000	6,360	527,138	Sep 30 06:15 PM
Marriott Tina	President and COO	Sep 26 '24	Sale	7.00	6,000	42,005	521,138	Sep 30 06:15 PM
Marriott Tina	Officer	Sep 26 '24	Proposed Sale	7.00	6,000	42,005		Sep 26 04:14 PM
Borgeson Blake	Director	Sep 17 '24	Sale	6.84	11,447	78,333	7,109,875	Sep 19 05:48 PM
Borgeson Blake	Director	Sep 17 '24	Proposed Sale	6.84	11,447	78,333		Sep 17 04:13 PM
Secora Michael	Chief Financial Officer	Sep 10 '24	Option Exercise	2.22	39,375	87,413	1,392,756	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 11 '24	Option Exercise	2.22	39,375	87,413	1,417,131	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 11 '24	Sale	6.32	15,000	94,730	1,402,131	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 10 '24	Sale	6.17	15,000	92,499	1,377,756	Sep 12 06:28 PM
Secora Michael	Officer	Sep 11 '24	Proposed Sale	6.32	15,000	94,730		Sep 11 05:15 PM
Secora Michael	Officer	Sep 10 '24	Proposed Sale	6.17	15,000	92,499		Sep 10 05:00 PM
Gibson Christopher	Chief Executive Officer	Sep 05 '24	Sale	6.14	20,000	122,800	762,656	Sep 06 04:57 PM
Gibson Christopher	Chief Executive Officer	Sep 04 '24	Sale	6.04	20,000	120,800	762,656	Sep 06 04:57 PM
Borgeson Blake	Director	Sep 03 '24	Sale	6.27	11,447	71,718	7,121,322	Sep 05 05:25 PM
Gibson Christopher	Officer	Sep 05 '24	Proposed Sale	6.14	20,000	122,800		Sep 05 11:43 AM
Gibson Christopher	Officer	Sep 04 '24	Proposed Sale	6.04	20,000	120,800		Sep 04 01:16 PM
Marriott Tina	President and COO	Aug 29 '24	Option Exercise	1.06	6,000	6,360	527,138	Sep 03 04:48 PM
Marriott Tina	President and COO	Aug 29 '24	Sale	7.56	6,000	45,376	521,138	Sep 03 04:48 PM
Borgeson Blake	Director	Sep 03 '24	Proposed Sale	6.27	11,447	71,717		Sep 03 04:27 PM
Gibson Christopher	Chief Executive Officer	Aug 30 '24	Option Exercise	2.48	5,000	12,400	762,656	Aug 30 04:26 PM
Marriott Tina	Officer	Aug 29 '24	Proposed Sale	7.56	6,000	45,376		Aug 29 04:53 PM
Gibson Christopher	Chief Executive Officer	Aug 29 '24	Option Exercise	2.48	5,000	12,400	757,656	Aug 29 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 28 '24	Option Exercise	2.48	5,000	12,400	752,656	Aug 28 04:12 PM
Gibson Christopher	Chief Executive Officer	Aug 27 '24	Option Exercise	2.48	5,000	12,400	747,656	Aug 27 04:10 PM
Gibson Christopher	Chief Executive Officer	Aug 26 '24	Option Exercise	2.48	5,000	12,400	742,656	Aug 26 04:42 PM
Gibson Christopher	Chief Executive Officer	Aug 23 '24	Option Exercise	2.48	5,000	12,400	737,656	Aug 23 05:25 PM
Borgeson Blake	Director	Aug 20 '24	Sale	7.12	11,447	81,532	7,132,769	Aug 22 06:48 PM
Borgeson Blake	Director	Aug 20 '24	Proposed Sale	7.12	11,447	81,533		Aug 20 04:25 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Option Exercise	2.22	39,375	87,413	1,355,968	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Option Exercise	2.22	39,375	87,413	1,380,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Sale	6.35	15,000	95,252	1,365,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Sale	6.35	15,000	95,182	1,340,968	Aug 15 05:24 PM
Secora Michael	Officer	Aug 14 '24	Proposed Sale	6.35	15,000	95,251		Aug 14 04:35 PM
Secora Michael	Officer	Aug 13 '24	Proposed Sale	6.35	15,000	95,183		Aug 13 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 07 '24	Sale	7.10	30,000	213,000	758,738	Aug 09 04:56 PM
Gibson Christopher	Chief Executive Officer	Aug 08 '24	Sale	6.50	20,000	130,000	758,738	Aug 09 04:56 PM
Borgeson Blake	Director	Aug 06 '24	Sale	6.82	11,447	78,083	7,144,216	Aug 08 05:23 PM
Gibson Christopher	Officer	Aug 08 '24	Proposed Sale	6.50	20,000	130,000		Aug 08 12:56 PM
Gibson Christopher	Officer	Aug 07 '24	Proposed Sale	7.10	30,000	213,000		Aug 07 01:34 PM
Borgeson Blake	Director	Aug 06 '24	Proposed Sale	6.82	11,447	78,083		Aug 06 04:50 PM
Marriott Tina	President and COO	Jul 25 '24	Option Exercise	1.06	6,000	6,360	541,457	Jul 29 06:16 PM
Marriott Tina	President and COO	Jul 25 '24	Sale	8.13	6,000	48,809	535,457	Jul 29 06:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience